IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
July 25, 2024 16:05 ET
|
IO Biotech
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech to Present at Jefferies Global Healthcare Conference
May 23, 2024 08:30 ET
|
IO Biotech
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
April 15, 2024 08:30 ET
|
IO Biotech
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
April 05, 2024 08:30 ET
|
IO Biotech
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 06, 2024 16:11 ET
|
IO Biotech
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
March 05, 2024 16:40 ET
|
IO Biotech
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results